Download PDF
Thromb Haemost 1993; 70(03): 386-388
DOI: 10.1055/s-0038-1649590
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Treatment of Severe Venous Thrombo-Embolism with Intravenous Hirudin (HBW 023): An Open Pilot Study

Florence Parent
1   The Department of Pneumology, Université Paris-Sud, Clamart, France
,
Françoise Bridey
2   The Department of Haematology, Université Paris-Sud, Clamart, France
,
Marie Dreyfus
2   The Department of Haematology, Université Paris-Sud, Clamart, France
,
Dominique Musset
3   The Department of Radiology, Université Paris-Sud, Clamart, France
,
Gilles Grimon
4   Department of Nuclear Medicine, Hôpital Antoine Béclère, Université Paris-Sud, Clamart, France
,
Pierre Duroux
1   The Department of Pneumology, Université Paris-Sud, Clamart, France
,
Dominique Meyer
2   The Department of Haematology, Université Paris-Sud, Clamart, France
,
Gérald Simonneau
1   The Department of Pneumology, Université Paris-Sud, Clamart, France
› Author Affiliations
Further Information

Publication History

Received 23 November 1992

Accepted after revision 05 April 1993

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Recombinant Hirudin (rH) is an anticoagulant agent with a specific antithrombin activity independent of antithrombin III. We report the results of the first open pilot study on the curative treatment of acute venous thrombo-embolism (VTE) with rH (HBW 023) in ten patients. The dose of rH tested was 0.07 mg/kg (i.v. bolus) followed by 0.05 mg kg-1 h-1 (i.v. infusion) for 5 days, without activated partial thromboplastin time (APTT) adjustment. Within the trial, no death, VTE recurrence or major bleeding was observed; lung scan pulmonary vascular obstruction improved from 44 to 37%, whereas the venographic Marder score was unchanged; APTT ratio ranged between 1.2 and 2.8. The dose of rH assessed in this study seems to be safe and efficient in the treatment of acute VTE.

 

  • References

  • 1 Marckwardt F, Nowak G, Stürzebecker J, Vogel G. Clinico-pharmacological studies with recombinant hirudin. Thromb Res 1988; 52: 393-400
    CrossrefPubMedGoogle Scholar
  • 2 Marckwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-388
    CrossrefPubMedGoogle Scholar
  • 3 Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and Standard heparin on thrombus growth in rabbits. Thromb Haemostas 1990; 63: 204-207
    PubMedGoogle Scholar
  • 4 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-665
    CrossrefPubMedGoogle Scholar
  • 5 Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, Heparin and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-1484
    CrossrefPubMedGoogle Scholar
  • 6 Meyer BH, Luus HG, Müller FO, Badenhorst PN, Röthig HJ. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 1990; 78: 268-270
    PubMedGoogle Scholar
  • 7 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
    CrossrefPubMedGoogle Scholar
  • 8 Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-1029
    PubMedGoogle Scholar
  • 9 Meyer G, Collignon MA, Guinet F, Jeffrey AA, Barritault L, Sors H. Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nucl Med 1990; 17: 315-319
    CrossrefPubMedGoogle Scholar
  • 10 Griessbach U, Sturzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347-350
    CrossrefPubMedGoogle Scholar
  • 11 Urokinase pulmonary embolism trial: phase I results: a cooperative. JAMA 1970; 214: 2163-2172
    CrossrefPubMedGoogle Scholar
  • 12 Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, Cate JWT. Comparison of subcutaneous low molecular-weight heparin with intravenous Standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
    CrossrefPubMedGoogle Scholar
  • 13 Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982
    CrossrefPubMedGoogle Scholar
  • 14 Maffrand JP, Bernat A, Delabassée D, Courtney M, Roitsch C, Defreyn G. Antithrombotic and haemorrhagic effects of rHV2-Lys47 hirudin compared with Standard heparin in rabbits. Thromb Haemostas 1989; 62: 434
    PubMedGoogle Scholar
  • 15 Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga J, Fareed J. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. Thromb Res 1989; 54: 435-445
    CrossrefPubMedGoogle Scholar
  • 16 Talbot M. Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis. Semin Thromb Hemostas 1989; 15: 293-301
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Girard P, Hauuy MP, Musset D, Simonneau G, Petitpretz P. Acute inferior vena cava thrombosis. Early results of heparin therapy. Chest 1989; 95: 284-291
    CrossrefPubMedGoogle Scholar
  • 18 Cook ED, Lloyd MJ, Bowcock SA, Pilcher MF. Monitoring during low dose heparin prophylaxis. N Engl J Med 1976; 294: 1066-1067
    PubMedGoogle Scholar
  • 19 Handeland GF, Abilgaard GF, Holm U, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractioned and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107-112
    CrossrefPubMedGoogle Scholar